Study: Chrondroitin Sulfate Can Aid Osteoarthritis

07 Jul 2015 --- Chrondroitin sulfate has a beneficial effect on the symptoms of osteoarthritis, according to a recent international review published in the journal Molecules.

The study also points out that not all chondroitin sulfate molecules on the market are the same: “Chondroitin sulfate products can be derived from a range of animal tissues, which could lead to products having different structures; and a variety of extraction and purification techniques can be used, resulting in different content, composition, purity, biological effects, clinical efficacy and safety,” the study said.

Furthermore, the investigators would like to see regulation in place to prevent the use of poor quality chondroitin as it could lead to the appearance of an effect other than the one intended: “Of importance, although some showed anti-inflammatory effects, others demonstrated weak effects, and some instances were even pro-inflammatory. This could be related to contaminants, which depend on the origin, production and purification process”, affirmed the article. 

Producer Bioiberica said its chrondroitin sulfate product CS b-Bioactive, is one of the brands on the market which can guarantee a robust module as well as a traceable manufacturing process. It also follows pharmaceutical manufacturing standards, and therefore it leads to a reliable end product that has shown clinical efficacy and safety in over 20 clinical trials and 14 million patients treated worldwide. 

“After more than ten years’ experience with this molecule, we remain committed to research and science and we continue to gather evidence that CS b-Bioactive, our chondroitin sulfate, is an effective and safe treatment for osteoarthritis patients”, affirmed Dr Josep Vergés, clinical pharmacologist and medical and scientific director at Bioiberica.

It is calculated that there are 40 million Europeans and 30 million Americans suffering from osteoarthritis; a chronic disease of the joints that causes pain, restrictions in mobility and a significant loss of quality of life.